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Coinfection with Plasmodium falciparummalaria and Epstein-Barr virus (EBV) is a major risk factor for endemic Burkitt lym-
phoma (eBL), still one of the most prevalent pediatric cancers in equatorial Africa. Althoughmalaria infection has been associ-
ated with immunosuppression, the precise mechanisms that contribute to EBV-associated lymphomagenesis remain unclear. In
this study, we used polychromatic flow cytometry to characterize CD8 T-cell subsets specific for EBV-derived lytic (BMFL1 and
BRLF1) and latent (LMP1, LMP2, and EBNA3C) antigens in individuals with divergent malaria exposure. Nomalaria-associated
differences in EBV-specific CD8 T-cell frequencies were observed. However, based on amultidimensional analysis of CD45RO,
CD27, CCR7, CD127, CD57, and PD-1 expression, we found that individuals living in regions with intense and perennial
(holoendemic) malaria transmission harbored more differentiated EBV-specific CD8 T-cell populations that contained fewer
central memory cells than individuals living in regions with little or no (hypoendemic) malaria. This profile shift was most
marked for EBV-specific CD8 T-cell populations that targeted latent antigens. Importantly, malaria exposure did not skew the
phenotypic properties of either cytomegalovirus (CMV)-specific CD8 T cells or the global CD8memory T-cell pool. These
observations define a malaria-associated aberration localized to the EBV-specific CD8 T-cell compartment that illuminates the
etiology of eBL.
First described in 1958 (1), endemic Burkitt lymphoma (eBL)remains one of the most prevalent childhood cancers in equa-
torial Africa. The average annual incidence is 2 per 100,000 chil-
dren, with a peak age range of 5 to 9 years (2–4). In 1964, Epstein-
Barr virus (EBV) was discovered in a tumor sample obtained from
a patient with eBL (5), and EBV DNA has subsequently been de-
tected in tumor cells from 95% of eBL cases (6). Thus, EBV was
identified as the first human tumor virus, with ensuing studies
revealing the virus-mediated oncogenic processes (7). However,
eBL is most common in children residing in areas with the highest
malaria transmission intensities (3, 8–10), an enigmatic observa-
tion that leaves the malaria-associated mechanisms involved in
the etiology of eBL insufficiently established by comparison.
Infection with EBV occurs early in most African populations,
and almost 100% of children are EBV seropositive by 3 years of age
(11, 12). Primary infection during childhood is typically asymp-
tomatic, whereas infection in young adults can result in acute
infectious mononucleosis (AIM), a self-limited lymphoprolifera-
tive disorder. To date, most immunologic studies of EBV infection
are based on healthy seropositive adults or cases of AIM among
adolescents in Europe or the United States (13). Collectively, these
studies show that CD8 cytotoxic T lymphocytes (CTL) are nec-
essary for immune surveillance and control of persistent EBV in-
fection (14, 15). The CTL response to EBV is directed against an
array of antigens expressed during the lytic and latent phases of the
viral life cycle (13–15), and control is associated with HLA class
I-restricted gamma interferon (IFN-) responses (16). Previous
studies have also demonstrated phenotypic and functional heter-
ogeneity among EBV-specific CD8 T-cell populations (17).
However, little is known about these cells when primary EBV in-
fection occurs during infancy or early childhood.
Beyond the early studies that revealed a geographic overlap
between eBL and areas of intense, perennial Plasmodium falcipa-
rummalaria transmission (regions of malaria holoendemicity) (8,
9), the malaria-driven mechanisms that contribute to eBL patho-
genesis remain obscure. In these regions of equatorial Africa,
more than 80% of children are chronically or repeatedly infected
with P. falciparum malaria by 5 years of age, and initial malaria
exposure occurs within the first few months of life (18, 19). It is
established that malaria parasites modulate and evade the host
immune system (20). Indeed, these properties underlie the hy-
pothesis that P. falciparum malaria suppresses immunity to EBV
during coinfection. In the early 1980s, a series of seminal studies
demonstrated that lymphocytes from malaria-infected individu-
als were unable to control the proliferation of EBV-transformed B
cells in relatively crude regression assays (21, 22). Although these
observations suggest that P. falciparum malaria infection disrupts
EBV-specific immunity, the effector cells or mediators responsible
for controlling EBV-infected B-cell growth were not identified,
and overall immune competence was not assessed in the small
number of individuals studied. More recently, an age-related de-
ficiency in IFN- recall responses to EBV lytic and latent antigens
was demonstrated in children (i.e., 5 to 9 years of age) with ho-
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loendemic malaria exposure compared to those from an area of
malaria hypoendemicity (23). In addition, EBV load in African
children correlates with malaria exposure (24, 25), further impli-
cating coinfection as a risk factor for eBL tumorigenesis. However,
it remains unclear how P. falciparum malaria might potentiate a
deficit in EBV-specific T-cell immunity and thus contribute to
eBL lymphomagenesis.
Two mutually compatible theories have been proposed to ex-
plain the relationship between EBV and P. falciparum malaria in
the etiology of eBL (26). The first suggests that malaria coinfection
increases the number of latently infected B cells by inducing poly-
clonal B-cell expansion and consequent lytic EBV reactivation
(27). In turn, the greater precursor frequency of EBV-infected B
cells increases the likelihood of c-myc translocation, which is a
hallmark of all BL tumors (28). The second theory argues that
EBV-specific T-cell responses are selectively altered during ma-
laria coinfection, either as a cause or consequence of enhanced
EBV replication, leading to impaired viral control and/or immune
surveillance (29, 30).
To provide direct evidence for the role of altered EBV-specific
T-cell immunity in eBL, we used polychromatic flow cytometry to
characterize EBV-specific CD8 T cells in a unique, well-charac-
terized cohort of individuals with divergent malaria exposure.
Specifically, 16-parameter flow cytometry panels were developed
to quantify differentiation, exhaustion, senescence, and homeo-
static potential within six distinct EBV-specific CD8 T-cell
populations and one CMV-specific CD8 T-cell population, all
restricted by HLA A*0201, and within the CD8 T-cell compart-
ment as a whole. By virtue of the highly multiplexed nature of our
measurements, cellular characteristics could be defined in exqui-
site detail. Furthermore, we employed recently developed data
analysis strategies to deconvolute these complex flow cytometry
data sets. Accordingly, probability binning (31) and frequency
difference gating (32) revealed dramatic differences between cell
populations in multidimensional space that eluded conventional
analytical approaches. Together, our analyses reveal an immuno-
logic aberration confined to the EBV-specific CD8 T-cell com-
partment that is associated with P. falciparum malaria exposure
and further illuminate the relationship between holoendemic ma-
laria and eBL.
MATERIALS AND METHODS
Study participants.Approval for this study was obtained from the Ethical
Review Committee at the Kenya Medical Research Institute (KEMRI) and
the Institutional Review Board for Human Studies, University Hospitals
of Cleveland, Case Western Reserve University; the latter was the institu-
tional affiliation for A.M.M. at the time of this study. Written informed
consent was obtained in all cases from study participants or parents of
minors.
Participant recruitment and sample collection were conducted in two
epidemiologically distinct areas of western Kenya: (i) Nyanza Province,
Kisumu District, in the sublocation of Kanyawegi; (ii) Rift Valley Prov-
ince, Nandi District, in the sublocation of Kipsamoite. The first study site
is situated on the shore of Lake Victoria, 10 km west of Kisumu; malaria
transmission in this area is holoendemic (i.e., intense and perennial). The
second study site is located in the highlands, 150 km northeast of Kisumu;
malaria transmission in this area is hypoendemic (i.e., sporadic with pe-
riodic outbreaks of malaria morbidity in a population with low parasite
prevalence) (33).
For this study, we collected blood samples from individuals with
known HLA class I genotypes and divergent malaria exposure histories
who experienced primary EBV infection prior to 3 years of age (25, 34).
No evidence of fever or anemia was present in these individuals at the time
of venous blood sampling; thus, any cases of malaria parasitemia were
asymptomatic.
Sample collection. Venous blood was collected in sodium-heparin-
ized tubes and transported to the KEMRI Center for Global Health Re-
search in Kisumu for processing within 3 h. Peripheral blood mononu-
clear cells (PBMCs) were separated from whole blood by Ficoll-Hypaque
density gradient centrifugation, counted, and then resuspended in freez-
ing medium comprising 90% heat-inactivated, filter-sterilized fetal bo-
vine serum and 10% dimethyl sulfoxide (Sigma). Aliquots of 6 million
cells/ml per vial were cooled overnight at a rate of1°C per minute prior
to long-term storage in vapor-phase liquid nitrogen. Samples were trans-
ported with a Centers for Disease Control and Prevention (CDC) import
permit using an MVE IATA-approved vapor-phase shipper to maintain
temperatures below180°C en route.
Tetrameric peptide-HLA A*0201 complexes. Soluble, biotinylated
peptide-HLA A*0201 (pHLA A*0201) monomers were produced and te-
tramerized with fluorochrome-conjugated streptavidin as described pre-
viously (35). The following peptides (95% purity; BioSynthesis) were
used for monomer production: (i) GLCTLVAML (GLC; EBV BMLF1,
residues 280 to 288), (ii) YVLDHLIVV (YVL; EBV BRLF1, residues 109 to
117), (iii) YLLEMLWRL (YLL; EBV LMP1, residues 125 to 133), (iv)
FLYALALLL (FLY; EBV LMP2, residues 356 to 364), (v) CLGGLLTMV
(CLG; EBV LMP2, residues 426 to 434), (vi) LLDFVRFMGV (LLD; EBV
EBNA3C, residues 284 to 293), and (vii) NLVPMVATV (NLV; CMV
pp65, residues 495 to 503).
Flow cytometry and data analysis. Samples were thawed and then
stained with pHLA A*0201 tetramers and a panel of fluorochrome-con-
jugated monoclonal antibodies as described previously (36). Data were
analyzed using FlowJo version 9.2 (Treestar Inc.), which contains plat-
forms for probability binning/frequency difference gating and SPICE (31,
32). Adjustments for multiple comparisons were not performed due to
considerable overlap between cell subsets (37). Instead, a more stringent
threshold for significance was set (P 0.01).
RESULTS
Development and validation of polychromatic flow cytometry
panels for the evaluation of EBV-specific CD8 T-cell immu-
nity. To evaluate the effects of P. falciparum malaria on EBV-
specific CD8 T-cell immunity, we conducted a cross-sectional
study of children and adults from regions where malaria is either
holoendemic or hypoendemic (34). Peripheral blood samples
were examined using two 16-parameter flow cytometry panels to
determine antigen specificity and molecular coexpression pat-
terns at the single-cell level (Fig. 1A and B). Reagents and staining
panels were developed as described previously (36). Assay proce-
dures were validated for rare event analysis using a set of test
samples (n 28), with previously defined epitope-specific CD8
T-cell responses corresponding to the HLA A*0201-restricted
specificities examined in this study. All pHLA A*0201 tetramers
were quality controlled using PBMCs from HLA A*0201 donors
and HLA A*0201 donors with no evidence of CMV or EBV in-
fection; no nonspecific staining was observed in either setting.
Individual samples were also evaluated repeatedly to ensure pro-
cedural reproducibility. This approach enabled us to interrogate
EBV-specific CD8T-cell populations with unprecedented preci-
sion and depth.
Immunodominance profiles among HLA A*0201-restricted
EBV-specific CD8 T-cell populations. Initially, we examined
the frequencies of CD8 T cells directed against six different HLA
A*0201-restricted EBV-derived epitopes. Four of these epitopes
(YLL, FLY, CLG, and LLD) are derived from latently expressed
proteins, and two (GLC and YVL) are derived from lytic-phase
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proteins. There are dramatic differences between these epitopes
with respect to the milieu and kinetics of antigen presentation to
the immune system. Remarkably, however, we found no signifi-
cant differences between the frequencies of CD8T cells targeting
latent and lytic epitopes (Fig. 2A). Moreover, no single epitope-
specific CD8 T-cell population was consistently immunodomi-
nant across the cohort as a whole. These observations held after
stratification of study participants for malaria exposure (data not
shown) and age (Fig. 2B). The similar distribution of these CD8
T-cell populations across all age groups suggests that the nature of
the EBV-specific response is set early in life and changes little over
time.
Distinct phenotypes characterize different EBV-derived
epitope-specific CD8 T-cell populations. Next, we examined
the phenotypic properties of EBV-specific CD8T cells across the
entire study population regardless of malaria exposure. Minor
phenotypic differences were observed in some EBV-specific CD8
T-cell populations by age. However, these were observed only in
exceedingly rare cell populations, and there was no clear relation-
ship between the populations that differed; for example, expres-
sion of the senescence marker CD57 was not consistently lower in
the youngest individuals (data not shown). On this basis, we sub-
sequently aggregated all study participants irrespective of age. In
order to minimize the contribution of nonspecific events
(“noise”), we stratified the data set according to the number of
cells collected on the flow cytometer and selected only those pop-
ulations that achieved a statistically rigorous minimum number of
antigen-specific events (Fig. 3; see also Fig. S1 in the supplemental
material).
Given the large number of measured parameters and the chal-
lenges associated with the interpretation of such complex multi-
variate data, our initial analyses focused on the differentiation
stage of EBV-specific CD8 T cells, defined by the coordinate
expression of CD45RO, CCR7, CD27, CD127, and CD57 (see Fig.
S2 in the supplemental material). Although CD57 typically defines
senescent cells (38), we have observed in previous analyses that
expression is not exclusively linked to advanced differentiation
(39), which complicates the categorization and nomenclature of
FIG 1 Gating strategy and flow cytometric staining patterns. (A) Gating strategy for identification of CD8T cells. Cell doublets were excluded from the analysis
on the basis of forward scatter area and height characteristics (FSC-A and FSC-H, respectively), and live (ViViD) CD3 lymphocytes were selected. Fluoro-
chrome aggregates were then excluded (not shown) prior to the selection of CD4 CD8 T cells for further analysis. (B) Representative staining patterns for
immunophenotypic markers within the total CD8 T-cell compartment (top row), and the identification of EBV-specific CD8 T-cell populations using pHLA
A*0201 tetramers (middle and bottom rows). Low-resolution plots are used for EBV-specific CD8 T-cell events to aid visualization of low-frequency popula-
tions. In the individual depicted here, clear CD8 T-cell populations are observed for all specificities with the exception of YLL.
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maturational subsets. In this light, we examined other phenotypic
categories separately within the CD57 and CD57 subsets. This
analysis showed that many of the CD57 cells directed against
both latent and lytic EBV-derived epitopes were central memory-
like cells, expressing various combinations of CD45RO, CCR7,
CD27, and CD127. Notably, EBV-specific CD8 T cells with a
naïve-like phenotype (CD45RO CCR7 CD27 CD127
CD57) were frequently observed, in line with previous reports in
other systems (40, 41). This is consistent with the recent descrip-
tion of stem cell-like memory T cells, which express many other
surface markers typically associated with antigen-inexperienced
naïve cells and likely represent a very early stage of memory T-cell
differentiation (42).
In further analyses, we examined the phenotypic properties of
EBV-specific CD8 T-cell populations in terms of homeostatic
potential (CD127), exhaustion (PD-1), and senescence (CD57).
Clear phenotypic differences were observed between CD8 T-cell
populations that targeted distinct EBV-derived antigens (Fig. 4).
Thus, substantial diversity exists within the CD8 T-cell response
to EBV, which likely reflects the complexity of antigen expression
and immunosurveillance. Despite this complexity, however,
CD8 T cells directed against the latent antigens FLY, CLG, and
YLL generally expressed markers consistent with the retention of
homeostatic potential in the relative absence of exhaustion/senes-
cence. In contrast, CD8 T cells directed against the lytic antigens
GLC and YVL more frequently displayed an exhausted/senescent
phenotype lacking homeostatic potential. Interestingly, CD8 T
cells specific for the latent epitope LLD (EBNA3C) exhibited sim-
ilar proportions of exhausted/senescent cells compared to the
antilytic populations, thereby suggesting that the biology of
EBNA3C expression may differ from that of other latent antigens.
Phenotypic differences between EBV-specific CD8 T cells
associated with malaria endemicity. Next, we stratified study
participants by malaria exposure and examined the phenotype of
EBV-specific, CMV-specific, and total CD8 T-cell populations.
Malaria exposure was determined as described previously (43),
based on well-defined epidemiologic parameters, and confirmed
with clinical or laboratory data. Specifically, blood-stage infection
in children occurs with 10% prevalence in regions where ma-
laria is hypoendemic, whereas childhood infection rates in regions
FIG 2 Frequencies of EBV-specific CD8 T cells. (A) Frequencies of EBV-specific CD8 T cells defined by pHLA A*0201 tetramer staining. (B) Frequencies of
EBV-specific CD8 T cells by age group (children ages 3 to 5 years, red; children/adolescents ages 5 to 18 years, yellow; adults, green). There were no significant
frequency differences between age groups for any of the depicted CD8T-cell specificities. Horizontal bars represent median values, and boxes delineate the 25th
and 75th percentiles.
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of malaria holoendemicity are consistently50% throughout the
year (44). Individuals from regions with strikingly divergent cu-
mulative malaria exposure (hypoendemic versus holoendemic)
were compared for this study, and two distinct approaches to data
analysis were employed.
In the first approach, the proportion of CD8 T cells that ex-
pressed each single marker was compared across both study groups
and any statistically significant differences were noted. Subsequently,
the proportion of CD8 T cells that expressed every combination of
two, three, four, or five markers was tested across the study groups.
These analyses were conducted for each EBV-specific CD8 T-cell
population and for the CMV-specific and total CD8T-cell popula-
tions. Figure 5 shows examples of the differences observed when du-
al-marker expression was examined within the EBV-derived GLC
epitope-specific CD8T-cell population. Study participants from re-
gions where malaria is hypoendemic (blue) had more CD45RO
CD127 and CD45RO CD57 T cells than individuals from ho-
loendemic (red) areas (P 0.003 and P 0.009, respectively) and
fewer CD45ROCD127 T cells (P 0.008).
FIG 3 Distribution of phenotypes within each antigen-specific CD8 T-cell
population, grouped by the number of events collected on the flow cytometer.
Data are shown for CD8T cells directed against EBV-derived latent antigens.
Pies depict data for samples where 1 to 5, 6 to 10, 11 to 20, or 20 antigen-
specific events were collected. Slices within each pie represent the proportion
of CD8 T cells expressing a particular combination of the markers analyzed.
Pies for each event category were compared by permutation analysis to deter-
mine if the distribution of phenotypes differed according to the number of
events collected. For example, among CD8 T cells specific for the FLY
epitope, the distribution of phenotypes observed when 1 to 5 events were
collected (pie 1) was significantly different from the distribution observed
when 20 events were collected (P  0.037). Similarly, the distribution dif-
fered significantly when 6 to 10 (pie 2) and 11 to 20 (pie 3) events were col-
lected (P  0.074 and P  0.002, respectively). Thus, the phenotype of FLY-
specific CD8 T cells was not considered in samples with less than 20 such
events. For all other latent-phase antigens, the distribution of phenotypes was
not significantly different when more than 5 events were collected; these pies
are highlighted with a black border. Therefore, for these specificities, only
study participants with fewer than 5 antigen-specific events were excluded
from the analysis. The numbers in the center of the pie represent the number of
study participants included in each group. Thus, FLY-specific CD8 T-cell
populations were analyzed in 20 of the 56 individuals (pie 4), while responses
to the CLG, YLL, and LLD epitopes were analyzed in 38, 29, and 41 of the 56
individuals, respectively (sum of pies 2 to 4). Of note, although the number of
antigen-specific events analyzed was low, sources of nonspecific binding were
rigorously excluded, and the total number of events collected ranged from
350,000 to 950,000. Data for CD8 T cells directed against EBV-derived lytic
antigens are shown in Fig. S1 in the supplemental material.
FIG 4 Relative frequencies of EBV-specific CD8 T cells expressing various
combinations of CD45RO, CD57, CD127, and PD-1 within each tetramer
population. Data are arranged in order of increasing differentiation, such that
the bar charts on the left side of the figure depict CD127 events and the bar
charts on the right side of the figure depict CD127 events. Within each sec-
tion, increasingly exhausted or senescent populations are found to the right.
For example, CD8 T cells expressing CD127 without markers of exhaustion
or senescence are represented on the far left; these are most evident within the
populations specific for YLL, LLD, GLC, and YVL. In contrast, exhausted or
senescent CD8 T cells without homeostatic potential are represented on the
far right; these are most evident within the populations specific for LLD, GLC,
and YVL. Bars represent median values for the depicted cell types (x axis key)
within CD8 T-cell populations specific for the listed EBV-derived epitopes
(right y axis labels). Hatched green (latent) and red (lytic) lines connect the
medians for each distinct phenotype to aid visual comparison within each
specificity.
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Similar analyses were performed for all combinations of phe-
notypic markers. Tables 1 and 2 list the phenotypically defined
CD8 T-cell subsets across all specificities that were significantly
elevated in study participants from regions where malaria is hy-
poendemic and holoendemic, respectively. In general, the num-
bers of cell types associated with less differentiated memory T-cell
populations (e.g., CD127 cells) were elevated in individuals from
regions with hypoendemic malaria, whereas the numbers of more
differentiated (e.g., CD27, CCR7), exhausted (PD-1), or se-
nescent (CD57) cells were elevated in those exposed to holoen-
demic malaria. Although no adjustments were made for multiple
comparisons, several comparisons were highly significant (P 
0.01), and taken together, the data present a uniform picture. Spe-
cifically, individuals with chronic/recurrent malaria exposure
have elevated levels of highly differentiated EBV-specific CD8 T
cells compared to those of individuals with little or no malaria
exposure. Importantly, no statistically significant phenotypic dif-
ferences between study groups were observed within either the
CMV-specific or the total CD8 T-cell populations (Tables 1 and
2). Thus, malaria exposure uniquely affects the EBV-specific
CD8 T-cell compartment.
Malaria-associated phenotypic differences in EBV-specific
CD8 T-cell populations pinpointed in multidimensional
space. The manual gating approach described above has two sig-
nificant limitations. First, any population differences that are only
manifest in multiple dimensions will be more difficult to resolve,
and appropriate gating strategies that discriminate such subsets
optimally may not be evident from examination of the dual-pa-
rameter histograms. Second, a large number of phenotypic popu-
lations are necessarily identified, leading to loss of significance
when correcting for multiple comparisons. To overcome these
limitations, we adopted a second approach to confirm and extend
our observations. Specifically, we used frequency difference gating
(32), a method that does not rely on serial bivariate analysis and
therefore has the potential to reveal population differences that
occur across multidimensional space.
Using this approach, we initially examined EBV-derived
GLC epitope-specific CD8 T cells (Fig. 6). The results con-
firmed and extended our previous analysis, in which CD8 T
cells with a central memory-like phenotype (CD45RO
CD127 and CD45RO CD57) were associated with hypoen-
demic malaria exposure (Table 1 and Fig. 5). Frequency differ-
ence gating revealed a phenotypic space defined by the
CD45RO CD27 CCR7 CD127 CD57 PD-1 expression
pattern that contained 9.9% of GLC-specific CD8 T cells from
individuals with hypoendemic malaria exposure and only 2.9%
of the corresponding CD8 T-cell population from individuals
with holoendemic malaria exposure (P 0.05). Thus, as in the
previous analysis, highly differentiated cells were enriched
within the GLC-specific CD8 T-cell compartment in individ-
uals with holoendemic malaria exposure.
Examination of the other specificities revealed more striking
differences (Fig. 6). In individuals with hypoendemic malaria ex-
posure, frequency difference gating identified an EBV-derived
FLY epitope-specific CD8 T-cell population that was highly en-
riched for central memory-like cells compared to the holoen-
demic group (27.7% versus 5.7%,P 0.0001). This difference was
not apparent with the first approach to data analysis. Further-
more, we found that individuals with hypoendemic malaria expo-
sure also had higher levels of central memory-like cells when re-
sponses to any latent epitope were pooled (P 0.001). Differences
according to malaria endemicity across pooled CD8 T-cell pop-
ulations specific for EBV-derived latent epitopes are summarized
in Fig. S3 in the supplemental material. No statistically significant
FIG5 Representative examples of phenotypic patterns within EBV-derived GLC-specific CD8T-cell populations that differed by malaria exposure. Horizontal
bars represent median values, and boxes delineate the 25th and 75th percentiles. Box colors depict malaria endemicity (hypoendemic, blue; holoendemic, red).
TABLE 1 Phenotypically defined CD8 T-cell subsets that were
significantly elevated in regions with hypoendemic malaria
Epitope
P value for indicated phenotype
CD45RO
CD127
CD45RO
CD57
CD45RO CCR7
CD57 CD127
CLG
GLC 0.003 0.009
LLD
YLL 0.031
YVL
CMV 0.808 0.151 0.230
CD8 0.151 0.837 0.250
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phenotypic differences between study groups were observed for
pooled EBV-derived lytic epitope-specific, CMV-specific, or total
CD8 T cells.
DISCUSSION
This is the first comprehensive study of EBV-specific CD8 T-cell
immunity in individuals, including children, who reside in a re-
gion of malaria endemicity that imparts a significantly elevated
risk for the development of eBL. Accordingly, the results pre-
sented here reveal previously unappreciated characteristics of the
human immune response to this common, chronic viral infection
and the potential role of altered immunity in susceptibility to cancer.
For epitopes presented by HLA A*0201, we found that EBV-
specific CD8 T cells directed against lytic and latent antigens
were equally represented across the study population as a whole,
even though the proteins are presumably expressed with different
kinetics and under different conditions in vivo. We also found that
the signatures of EBV-specific T-cell immunity are largely set follow-
ing primary infection and appear to change little over time, as no
phenotypic differences were linked to age. Furthermore, although the
immune system is thought to “see” latent antigens constantly, CD8
T cells directed against these epitopes generally retained homeostatic
potential and were rarely exhausted/senescent. In contrast, CD8 T
cells directed against lytic antigens, the expression of which is thought
to be episodic and infrequent, were more likely to display an exhaust-
ed/senescent phenotype lacking homeostatic potential. Given the
prevalent hypothesis that such differences are related to antigen ex-
posure, these observations suggest the occurrence of frequent EBV
reactivations in the overall study population.
TABLE 2 Phenotypically defined CD8 T-cell subsets that were significantly elevated in regions with holoendemic malaria
Epitope
P value for indicated phenotype
CD45RO
CD127
CD45RO
CCR7
CD45RO CCR7
CD127 PD1
CD45RO
CD127
CD27 CD57
CD127 CD45RO
CD27
CD127
CLG 0.015 0.087 0.016
GLC 0.008 0.003
LLD 0.010
YLL
YVL 0.013
CMV 0.566 0.621 0.791 0.116 0.296 0.650 0.988
CD8 0.520 0.710 0.264 0.446 0.680 0.608 0.192
FIG 6 Frequency difference gating reveals CD8 T-cell subsets that are altered by malaria exposure. A subset of CD45RO CD27 CCR7 CD127 CD57
PD-1 (central memory-like) EBV-derived GLC-specific (top) and FLY-specific (middle) CD8 T cells is diminished in individuals from regions with holoen-
demic malaria. In the pooled data from all CD8 T cells that target latent antigens, a subset that includes central memory-like cells is dramatically reduced in
individuals with holoendemic malaria exposure.
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Interestingly, CD8 T cells directed against the latent epitope
LLD (EBNA3C) displayed phenotypic characteristics similar to
those observed for the corresponding lytic antigen-specific popu-
lations; this finding is in keeping with previous studies that detail
the typical immunodominance of EBNA3C (13) and suggests
quantitatively enhanced or qualitatively distinct presentation of
this protein among the latent antigens studied.
An intriguing observation from our data is the identification of
EBV-specific CD8 T cells with a naïve-like (CD45RO CD27
CCR7 CD127 CD57) phenotype. Within the context of this
study, the functional capacity of these EBV-experienced naïve-like
CD8 T cells is as yet unknown. It is likely that such cells populate
a very early differentiated memory pool (41) and perhaps even
constitute an antigen-specific “stem cell-like memory” popula-
tion (42). However, further work is required to clarify the biolog-
ical significance of this observation.
The features of EBV-specific CD8 T-cell immunity described
above were independent of malaria exposure yet were observed in
individuals who typically acquire the virus during early childhood
(25). Nonetheless, malaria coinfections were associated with ad-
ditional phenotypic differences between CD8T-cell populations
specific for latent epitopes and the lytic epitope GLC (BMLF1),
which displayed characteristics of a more differentiated stage in
individuals from regions of malaria holoendemicity. Thus, despite
the fact that all study participants were healthy, distinct malaria-
associated irregularities in EBV-specific CD8 T-cell immunity
were apparent. Overall, these results support a combined role for
early primary EBV infection and cumulative malaria exposure in
EBV-specific T-cell immune dysregulation.
Due to the cross-sectional nature of this study and the rela-
tively low incidence of eBL, we were not able to address directly the
causal relationship between EBV, P. falciparum malaria, and eBL.
However, our data offer new evidence that addresses two long-
standing questions in the field.
First, as with any immunologic study in humans that attempts
to inform pathogenic mechanisms, it is critical to understand
whether the observed deficits represent cause or effect in the dis-
ease process. Our previous study revealed a deficiency in IFN-
production by EBV-specific CD8 T cells in children residing in a
region with holoendemic malaria (23). However, the events that
precede this immune deficiency are unclear. On that basis, we
postulated that more detailed studies of EBV-specific CD8T-cell
immunity in areas with divergent malaria endemicity might pro-
vide a better window into the complex etiology of eBL. Given the
remarkable diversity of T cells, simple immunophenotypic analy-
ses could miss fine subsets critical to the understanding of this
relationship. In addition, although EBNA1 is the only EBV-
derived protein expressed in eBL (45), the risk for disease may be
set when T cells specific for a wide variety of lytic and latent anti-
gens are generated. For these reasons, we used a sophisticated flow
cytometric approach optimized for rare event analysis to demon-
strate that a loss of central memory-like EBV-specific CD8T cells
is associated with malaria exposure. Such immunologic perturba-
tions within the EBV-specific CD8 T-cell compartment could
predispose to the functional deficits that accompany eBL (46).
Second, our study addresses the long-standing question of
whether eBL is associated with a generalized, malaria-induced
suppression of T-cell immunity (21, 22, 47). Our data demon-
strate that EBV-specific, but not CMV-specific or total, CD8
T-cell populations show significant differences associated with
malaria exposure. These findings are consistent with previous
studies showing that T-cell responses to malaria antigens and
nonspecific mitogens are equally robust across study populations
and age groups (46). Thus, malaria exposure uniquely impacts the
EBV-specific CD8 T-cell compartment, which argues against a
role for generalized immune suppression in the pathogenesis
of eBL.
In the context of a cross-sectional study, however, it is not
possible to discern how the observed immunologic differences
arise. Recently, a malarial antigen capable of inducing the reacti-
vation of latent EBV was identified (48), possibly providing a
mechanistic explanation for our findings. In this scenario, re-
peated malaria infections induce EBV reactivation, thereby seed-
ing new, potentially highly activated and dividing B cells (27),
which consequently increase the risk of B-cell transformation. As
EBV-specific CD8 T cells attempt to control these frequent reac-
tivations, their differentiation is accelerated and the pool of cen-
tral memory cells for such specificities is selectively depleted. This
possibility is supported by seroprofiling studies, which demon-
strate that elevated antibody titers to viral capsid antigen (VCA)
and the Z Epstein-Barr replication activator (ZEBRA) protein are
associated with holoendemic malaria exposure (49). An elevation
in these antibody titers signifies viral reactivation (50), and higher
VCA antibody titers were observed prior to the development of
eBL in a study of Ugandan children (51, 52). In addition, malaria
infection in concert with EBV reactivation may modulate ele-
ments of the innate immune system that influence T-cell matura-
tion and differentiation (53, 54).
In summary, we have demonstrated that a select set of EBV-
derived antigen-specific CD8 T cells is altered in individuals
coinfected with P. falciparum malaria and at increased risk for
eBL. These findings inform our studies of eBL pathogenesis and
suggest that EBV-targeted immune interventions in the setting of
holoendemic malaria might hold promise for the prevention of
this devastating pediatric malignancy.
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